Research
Hormonal
Long-acting GLP-1 agonists and incretin multi-agonists have demonstrated clinically significant efficacy in reducing body weight.
Practitioners may consider GLP-1 agonists and incretin multi-agonists as effective options for weight management in obese patients.
StrongSupportsmedium confidence
Long-acting GLP-1 agonists and incretin multi-agonists have demonstrated clinically significant efficacy in reducing body weight among hypoglycemic drugs in a number of pilot and larger studies.
Why this rating
Based on the mention of pilot and larger studies indicating significant efficacy.
Source
Possibilities of using glucagon-like peptide-1 agonists and incretin multi-agonists in pharmacotherapy of obesity and metabolic syndrome
Vadim V. Abramov et al. · Glavvrač (Chief Medical Officer) · 2024
DOI 10.33920/med-03-2407-03
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →